[go: up one dir, main page]

MX2012001061A - Hidrogeles biodegradables insolubles en agua a base de polietilenglicol. - Google Patents

Hidrogeles biodegradables insolubles en agua a base de polietilenglicol.

Info

Publication number
MX2012001061A
MX2012001061A MX2012001061A MX2012001061A MX2012001061A MX 2012001061 A MX2012001061 A MX 2012001061A MX 2012001061 A MX2012001061 A MX 2012001061A MX 2012001061 A MX2012001061 A MX 2012001061A MX 2012001061 A MX2012001061 A MX 2012001061A
Authority
MX
Mexico
Prior art keywords
main frame
water
frame portions
insoluble
hydrogel
Prior art date
Application number
MX2012001061A
Other languages
English (en)
Other versions
MX343925B (es
Inventor
Ulrich Hersel
Harald Rau
Dirk Vetter
Mathias Krusch
Tobias Voigt
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Publication of MX2012001061A publication Critical patent/MX2012001061A/es
Publication of MX343925B publication Critical patent/MX343925B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Colloid Chemistry (AREA)

Abstract

La presente invención se refiere a hidrogeles insolubles en agua a base de polietilenglicol biodegradables que comprende porciones de armazón principal que están interconectadas por enlaces hidrolíticamente degradables, las porciones de armazón principal comprenden además grupos funcionales reactivos, en donde el hidrogel insoluble en agua se caracteriza además porque la relación entre el periodo de tiempo para la degradación completa del hidrogel por hidrólisis de los enlaces degradables en productos de degradación hidrosolubles que comprenden una o más porciones de armazón principal y el periodo de tiempo para liberación de los primeros 10% molares de productos de degradación hidrosolubles que comprenden una o más porciones de armazón principal con base en la cantidad total de porciones de armazón principal en el hidrogel es mayor que 1 e igual a o menor que 2. La invención se refiere además a conjugados de estos hidrogeles con ligandos o grupos de ligación, profármacos y composiciones farmacéuticas, así como a su uso en un medicamento.
MX2012001061A 2009-07-31 2010-07-30 Hidrogeles biodegradables insolubles en agua a base de polietilenglicol. MX343925B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09167026 2009-07-31
EP09172339 2009-10-06
PCT/EP2010/061155 WO2011012715A1 (en) 2009-07-31 2010-07-30 Biodegradable polyethylene glycol based water-insoluble hydrogels

Publications (2)

Publication Number Publication Date
MX2012001061A true MX2012001061A (es) 2012-03-26
MX343925B MX343925B (es) 2016-11-29

Family

ID=43027631

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001061A MX343925B (es) 2009-07-31 2010-07-30 Hidrogeles biodegradables insolubles en agua a base de polietilenglicol.

Country Status (22)

Country Link
US (1) US11559482B2 (es)
EP (2) EP2459220B1 (es)
JP (1) JP5904941B2 (es)
KR (1) KR101770844B1 (es)
CN (1) CN102573913B (es)
AU (1) AU2010277556B2 (es)
BR (1) BR112012002280B1 (es)
CA (1) CA2769162C (es)
ES (1) ES2833035T3 (es)
HR (1) HRP20201609T1 (es)
HU (1) HUE052816T2 (es)
IL (1) IL217743A (es)
LT (1) LT2459220T (es)
MX (1) MX343925B (es)
MY (1) MY156872A (es)
NZ (1) NZ597960A (es)
PL (1) PL2459220T3 (es)
RU (1) RU2554854C9 (es)
SG (1) SG177761A1 (es)
SI (1) SI2459220T1 (es)
WO (1) WO2011012715A1 (es)
ZA (1) ZA201200686B (es)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3004716C (en) 2008-04-29 2022-04-12 Ascendis Pharma Endocrinology Division A/S Pegylated recombinant human growth hormone compounds
AU2010277559B2 (en) * 2009-07-31 2016-08-11 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
SG178195A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Long acting insulin composition
NZ599583A (en) 2009-10-29 2013-09-27 Ascendis Pharma As Sterilization of biodegradable hydrogels
SG181648A1 (en) 2009-12-15 2012-07-30 Ascendis Pharma As Dry growth hormone composition transiently linked to a polymer carrier
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US10451897B2 (en) 2011-03-18 2019-10-22 Johnson & Johnson Vision Care, Inc. Components with multiple energization elements for biomedical devices
WO2012151051A1 (en) * 2011-05-03 2012-11-08 Telik, Inc. Excipient compatibility with ezatiostat
CN103889434B (zh) 2011-06-21 2017-02-15 Bvw控股公司 含有乳香酸的医疗装置
HK1198913A1 (en) 2011-08-12 2015-06-19 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
IN2014CN00989A (es) * 2011-08-12 2015-04-10 Ascendis Pharma As
CA2843881C (en) * 2011-08-12 2020-05-26 Ascendis Pharma A/S Sustained release composition of prostacyclin
KR20140103099A (ko) 2011-10-12 2014-08-25 아센디스 파마 옵탈몰로지 디비젼 에이/에스 안구 병태의 예방 및 치료
KR20150000464A (ko) * 2011-11-03 2015-01-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 펩티드의 방출가능한 연결을 위한 티로신 기재의 링커
US8857983B2 (en) 2012-01-26 2014-10-14 Johnson & Johnson Vision Care, Inc. Ophthalmic lens assembly having an integrated antenna structure
HK1205697A1 (zh) 2012-04-25 2015-12-24 Ascendis Pharma A/S 含有羟基的药物的前药
WO2014002039A1 (en) * 2012-06-27 2014-01-03 Shire Ag Amphetamine prodrugs
PT3321254T (pt) 2012-08-21 2020-10-20 Janssen Pharmaceutica Nv Haptenos de aripiprazol e seu uso em imunoensaios
CA2882489A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
PT2888284T (pt) 2012-08-21 2022-11-18 Janssen Pharmaceutica Nv Anticorpos dirigidos contra haptenos de risperidona e a sua utilização
PT2888593T (pt) 2012-08-21 2018-12-12 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilizações dos mesmos
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
JP6270845B2 (ja) 2012-08-21 2018-01-31 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールに対する抗体及びその使用
PL2888258T3 (pl) * 2012-08-21 2019-10-31 Janssen Pharmaceutica Nv Hapteny paliperydonu
CN110054694B (zh) 2012-08-21 2024-02-20 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
MX370543B (es) * 2012-10-11 2019-12-17 Ascendis Pharma Ophthalmology Div A/S Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
WO2014056915A1 (en) * 2012-10-11 2014-04-17 Ascendis Pharma A/S Diagnosis, prevention and treatment of diseases of the joint
JP6271566B2 (ja) * 2012-10-11 2018-01-31 アセンディス ファーマ エー／エス ヒドロゲルプロドラッグ
HK1214151A1 (zh) 2012-12-07 2016-07-22 Ascendis Pharma A/S 载体连接型前列腺素类前药
US20140271885A1 (en) * 2013-03-15 2014-09-18 Intezyne Technologies, Inc. Copolymers for stable micelle formulations
DK2988732T3 (da) * 2013-04-22 2023-06-26 Ascendis Pharma As Modificerede hydrogeler
WO2014173759A1 (en) 2013-04-22 2014-10-30 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing modified drugs
ES2966631T3 (es) 2013-06-19 2024-04-23 Univ California Estructuras químicas para el suministro localizado de agentes terapéuticos
RU2543375C1 (ru) * 2013-07-29 2015-02-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный университет" Комплексное соединение производного метилурацила с органической кислотой и способ его получения
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
JP2016534984A (ja) 2013-10-01 2016-11-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ アフィニティークロマトグラフィーのためおよび治療薬の半減期の延長のための化合物
AU2014333953C1 (en) * 2013-10-08 2020-06-25 Ascendis Pharma A/S Hydrogel-linked IL-1ra prodrug
CN103554296B (zh) * 2013-10-12 2015-09-16 天津大学 一种亚油酸改性葡聚糖及制备高分子脂质体的方法
US20160296600A1 (en) 2013-11-11 2016-10-13 Ascendis Pharma Relaxin Division A/S Relaxin Prodrugs
US9675607B2 (en) * 2013-11-13 2017-06-13 Northwestern University Epimorphic regeneration and related hydrogel delivery systems
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN103706233A (zh) * 2013-12-17 2014-04-09 杨亮月 一种环氧乙烷零排放处理体系及方法
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
LT3107563T (lt) 2014-02-21 2021-07-12 Ecole Polytechnique Fédérale De Lausanne (Epfl) Epfl-Tto Gliko-nukreipiantys terapiniai agenai
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
JP6625550B2 (ja) 2014-03-14 2019-12-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｃｏ複合体および治療薬の送達のための方法
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
BR112017000813B1 (pt) 2014-07-17 2021-03-16 The Regents Of The University Of California sistemas de gel microporoso, usos de uma pluralidade de partículas de microgel em uma solução aquosa e um agente de recozimento, de camadas de sequestrantes covalentemente estabilizados de partículas de microgel, e de um sequestrante covalentemente estabilizado de partículas de microgel com espaços intersticiais, bem como método para a preparação de partículas de microgel
ES2993327T3 (en) 2014-08-06 2024-12-27 Ascendis Pharma As Prodrugs comprising an aminoalkyl glycine linker
US10361404B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Anodes for use in biocompatible energization elements
US9383593B2 (en) 2014-08-21 2016-07-05 Johnson & Johnson Vision Care, Inc. Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators
US9793536B2 (en) 2014-08-21 2017-10-17 Johnson & Johnson Vision Care, Inc. Pellet form cathode for use in a biocompatible battery
US9923177B2 (en) * 2014-08-21 2018-03-20 Johnson & Johnson Vision Care, Inc. Biocompatibility of biomedical energization elements
US10381687B2 (en) 2014-08-21 2019-08-13 Johnson & Johnson Vision Care, Inc. Methods of forming biocompatible rechargable energization elements for biomedical devices
US9941547B2 (en) 2014-08-21 2018-04-10 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes and cavity structures
US9715130B2 (en) 2014-08-21 2017-07-25 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form separators for biocompatible energization elements for biomedical devices
US9599842B2 (en) 2014-08-21 2017-03-21 Johnson & Johnson Vision Care, Inc. Device and methods for sealing and encapsulation for biocompatible energization elements
US10361405B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes
US10627651B2 (en) 2014-08-21 2020-04-21 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
JP6723509B2 (ja) 2014-10-24 2020-07-15 日油株式会社 環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体
KR20250059541A (ko) 2014-11-18 2025-05-02 아센디스 파마 엔도크리놀로지 디비전 에이/에스 신규한 중합체성 hGH 프로드러그
PT3220892T (pt) 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Formas de dosagem de hormona do crescimento de longa ação
EP3303365A4 (en) 2015-05-29 2019-04-24 Ascendis Pharma Inc. PRODRUGS WITH A PYROGLUTAMATE LINKER
KR102725051B1 (ko) 2015-09-23 2024-11-04 제넨테크, 인크. 항-vegf 항체의 최적화된 변이체들
US11458041B2 (en) * 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
EP3373870A4 (en) 2015-11-12 2019-07-10 University Of Virginia Patent Foundation COMPOSITIONS AND METHODS FOR VAS OCCLUSAL CONSUMER PREVENTION AND THEIR REVERSAL
WO2017106501A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
WO2017101883A1 (zh) * 2015-12-18 2017-06-22 韩捷 一种可在生理条件下降解的水凝胶
US10413616B2 (en) * 2015-12-23 2019-09-17 Viking Scientific, Inc. Hydrogel prodrug for treatment
WO2017142879A1 (en) 2016-02-16 2017-08-24 The Regents Of The University Of California Methods for immune system modulation with microporous annealed particle gels
US10345620B2 (en) 2016-02-18 2019-07-09 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices
BR112018017091A2 (pt) 2016-03-01 2019-01-02 Ascendis Pharma Bone Diseases As profármacos de pth
EP3439670A4 (en) 2016-04-08 2019-11-27 The Regents of the University of California MODIFIED HYALURONIC ACID HYGELS AND PROTEINS FOR THE TEMPORARY RELEASE OF BIOLOGICAL ACTIVE SUBSTANCES
CN105963792B (zh) * 2016-04-29 2019-03-22 深圳迈普再生医学科技有限公司 医用水凝胶组合物，医用水凝胶及其制备方法与应用
EP3484523A1 (en) 2016-07-13 2019-05-22 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
NZ751745A (en) 2016-09-29 2023-05-26 Ascendis Pharma Bone Diseases As Pth compounds with low peak-to-trough ratios
ES3012647T3 (en) 2016-09-29 2025-04-09 Ascendis Pharma Bone Diseases As Controlled-release pth compounds
HUE062117T2 (hu) 2016-09-29 2023-09-28 Ascendis Pharma Growth Disorders As Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
CN109789189B (zh) 2016-09-29 2024-01-23 阿森迪斯药物骨疾病股份有限公司 控释pth化合物的剂量方案
CA3051055A1 (en) 2016-12-29 2018-07-26 Tempo Therapeutics, Inc. Methods and systems for treating a site of a medical implant
US12383421B2 (en) 2017-01-05 2025-08-12 Contraline, Inc. Contraceptive devices
HRP20231297T1 (hr) 2017-03-10 2024-02-02 University Of Louisville Research Foundation, Inc. Fasl-konstruirani biomaterijali s imunomodulacijskom funkcijom
CA3055985A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN108864258A (zh) * 2017-05-12 2018-11-23 北京康明海慧生物科技有限公司 具有抑制肿瘤功能的peg化多肽及其制备方法与应用
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
CN107583104B (zh) * 2017-10-31 2020-12-01 无锡中科光远生物材料有限公司 一种可注射的用于脊柱修复的凝胶材料
BR112020008631A2 (pt) * 2017-11-02 2020-10-20 Tarsius Pharma Ltd. conjugado de fosforilcolina-tuftsina para tratamento de inflamação ocular
CN107880288A (zh) * 2017-11-29 2018-04-06 桂林华诺威生物科技有限公司 一种透明质酸钠凝胶的制备方法
CN108096630B (zh) * 2018-01-29 2020-09-04 暨南大学 一种载淫羊藿苷和去铁胺的聚乳酸基骨组织支架及制备方法和应用
MA52662A (fr) 2018-03-28 2021-02-17 Ascendis Pharma Oncology Div A/S Conjugués d'il-2
FR3079421B1 (fr) * 2018-03-28 2024-11-15 Edix Sa Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
CN110865130B (zh) * 2018-08-27 2023-08-22 北京海晶生物医药科技有限公司 一种盐酸奥洛他定及其有关物质的检测方法
EP3856256A1 (en) 2018-09-26 2021-08-04 Ascendis Pharma A/S Novel hydrogel conjugates
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
CN111077235B (zh) * 2018-10-19 2023-09-08 重庆医药工业研究院有限责任公司 一种测定2-[(2-甲基-5-溴苯基)甲基]-5-(4-氟苯基)噻吩杂质的方法
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020141223A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Induction of sustained local inflammation
TWI856997B (zh) * 2019-01-04 2024-10-01 丹麥商阿仙帝斯製藥公司 模式辨別受體(pattern recognition receptor)促效劑的共軛物
CA3125541A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
CN113316452A (zh) * 2019-01-04 2021-08-27 阿森迪斯药物肿瘤股份有限公司 先天性免疫激动剂的持续局部药物水平
KR102891411B1 (ko) 2019-02-11 2025-11-25 아센디스 파마 본 디지즈 에이/에스 Pth 접합체의 액체 약학 제제
JP7524206B2 (ja) 2019-03-04 2024-07-29 アセンディス ファーマ エンドクライノロジー ディヴィジョン エー／エス １日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
WO2020247776A1 (en) * 2019-06-07 2020-12-10 Likarda, LLC Tunable degradation in hydrogel microparticles
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
TW202114738A (zh) 2019-06-21 2021-04-16 丹麥商阿仙帝斯製藥公司 抗ctla4結合物
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
AU2020296297B2 (en) 2019-06-21 2025-06-12 Ascendis Pharma A/S Conjugates of heteroaromatic nitrogen-comprising compounds
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
AU2020296295B2 (en) 2019-06-21 2025-05-29 Ascendis Pharma A/S Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
CN114026080A (zh) * 2019-06-21 2022-02-08 阿森迪斯药物股份有限公司 含有提供π-电子对的杂芳族氮的化合物的缀合物
WO2020254609A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
PE20220902A1 (es) * 2019-06-26 2022-05-30 Biorchestra Co Ltd Nanoparticulas micelares y sus usos
US20230133656A1 (en) * 2019-07-03 2023-05-04 Molly Sandra Shoichet Hydrogel compositions and uses thereof
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用
KR20220056192A (ko) * 2019-08-29 2022-05-04 폴 더글라스 고드프린 경구 전달 제형으로서의 하이드로겔, 이를 제조하고 사용하는 방법
TW202128141A (zh) * 2019-11-19 2021-08-01 美商盧伯利索先進材料有限公司 用雙縮二胍鹽化之聚胺酯組成物
AU2020419444A1 (en) 2020-01-03 2022-06-09 Ascendis Pharma A/S Conjugates undergoing intramolecular rearrangements
CN111138293B (zh) * 2020-01-10 2023-07-07 蚌埠丰原医药科技发展有限公司 一种用微通道反应器合成富马酸伊布利特中间体的方法
CA3166738A1 (en) 2020-02-06 2021-08-12 Charles D. Blizzard Travoprost compositions and methods for treating ocular diseases
KR102375663B1 (ko) * 2020-03-24 2022-03-16 재단법인대구경북과학기술원 무손실 세포 염색 방법 및 장치
FI3884929T3 (fi) 2020-03-25 2023-08-07 Ocular Therapeutix Inc Tyrosiinikinaasi-inhibiittoria sisältävä silmäimplantti
WO2021224169A1 (en) 2020-05-04 2021-11-11 Ascendis Pharma A/S Hydrogel irradiation
CN113694261B (zh) * 2020-05-21 2022-09-09 江苏百赛飞生物科技有限公司 一种抗菌复合涂层及其制备方法和制品
US20210369651A1 (en) * 2020-05-28 2021-12-02 Sollievo Pharmaceuticals, Inc Parenteral delivery of avizafone
IL298642A (en) 2020-06-03 2023-01-01 Ascendis Pharma Oncology Div A/S il-2 sequences and uses thereof
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
EP4192508A1 (en) 2020-08-05 2023-06-14 Ascendis Pharma A/S Conjugates comprising reversible linkers and uses thereof
JP2023540701A (ja) 2020-08-28 2023-09-26 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス グリコシル化ｉｌ－２タンパク質及びその使用
EP4217004A1 (en) 2020-09-28 2023-08-02 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
CN112316156B (zh) * 2020-10-27 2022-03-15 四川大学 具抗氧化和抗菌性的胶原蛋白修复膜、其制备方法及应用
KR102437315B1 (ko) * 2020-11-02 2022-08-30 아주대학교산학협력단 하이브리드 하이드로겔 및 이의 생의학적 용도
CN116744984A (zh) 2020-12-28 2023-09-12 达沃有限公司 包含蛋白质和多官能化改性的基于聚乙二醇的交联剂的反应性干粉状止血材料
BR112023018802A2 (pt) 2021-04-01 2023-10-31 Ascendis Pharma As Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação
CN113304139B (zh) * 2021-06-30 2022-04-29 贵州医科大学 Viniferifuran在制备黄嘌呤氧化酶抑制药物中的应用
CN113398145B (zh) * 2021-07-02 2022-10-14 合肥康诺生物制药有限公司 含nad与氨氯地平的药物组合物及其用途
CN113461979A (zh) * 2021-07-19 2021-10-01 吉林大学 一种通过血红蛋白催化交联的仿贻贝类水凝胶的制备方法
MX2024006698A (es) 2021-12-13 2024-06-19 Ascendis Pharma Oncology Div A/S Tratamientos de cancer con agonistas de los receptores tipo toll 7 y 8 (tlr7/8).
CN114469926B (zh) * 2022-01-28 2023-06-27 吉林省健维天然生物科技有限公司 二氢槲皮素的新用途及二氢槲皮素水凝胶的制备方法
CN115073769B (zh) * 2022-05-30 2025-06-10 浙江大学 一种促组织再生的活性氧响应超分子水凝胶及其制备方法
CN115109275B (zh) * 2022-08-29 2022-11-01 杭州艾名医学科技有限公司 一种动态交联可降解水凝胶、制备方法及应用
CN115444840B (zh) * 2022-09-15 2023-08-25 四川大学 一种前药、两性离子水凝胶及其制备方法、应用
CN115322397B (zh) * 2022-09-23 2024-04-30 福州大学 一种预防术后腹腔粘连的两性离子水凝胶及其制备方法
CN115537017B (zh) * 2022-09-27 2023-09-01 四川大学 一种水凝胶及其制备方法和应用
WO2024094673A1 (en) 2022-11-02 2024-05-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
WO2024118480A1 (en) * 2022-11-28 2024-06-06 Epiphany Biosciences Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses
CN115873267B (zh) * 2022-11-30 2024-12-13 南京理工大学 一种具有电化学发光特性的柔性导电水凝胶及应用
CN120897764A (zh) 2023-04-11 2025-11-04 视尔普斯眼科公司 包含阿西替尼多晶型物iv的眼部植入物
WO2025051711A1 (en) 2023-09-04 2025-03-13 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease
US20250228774A1 (en) * 2024-01-11 2025-07-17 Boston Scientific Scimed, Inc. Systems and methods for accelerated hydrolysis of polysaccharide-based hydrogels
CN118652658B (zh) * 2024-05-28 2025-01-21 中国林业科学研究院林产化学工业研究所 一种锂硫电池正极水溶性自修复粘结剂、其制备方法及其应用
CN118459754B (zh) * 2024-07-10 2024-10-08 吉林大学 一种聚氨基酸及其制备方法和水凝胶、慢性创面敷料
CN119023860B (zh) * 2024-10-28 2025-02-14 晶易医药科技(成都)有限公司 一种氟轻松氢醌维a酸乳膏的含量检测方法
CN119661840A (zh) * 2024-12-12 2025-03-21 西湖大学 一种抗垢两性离子水凝胶及其制备方法与应用
CN119792314A (zh) * 2025-01-07 2025-04-11 河南农业大学 紫杉醇在增强替加环素抗菌作用中的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9306038A (pt) 1992-02-28 1998-01-13 Univ Texas Hidrogéis biodegradáveis fotopolimerizáveis como materiais de contato de tecidos e condutores de liberação controlada
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
CA2479810A1 (en) 2002-04-04 2003-10-16 Enzon, Inc. Polymeric acyl derivatives of indoles
US7776240B2 (en) * 2003-01-17 2010-08-17 Cornell Research Foundation, Inc. Injectable hydrogel microspheres from aqueous two-phase system
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
KR101128320B1 (ko) 2003-05-23 2012-04-12 넥타르 테라퓨틱스 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
US7968085B2 (en) * 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
DE102004051715A1 (de) 2004-10-23 2005-06-30 Clariant Gmbh Flüssigwaschmittel enthaltend Farbfixiermittel
KR100665672B1 (ko) * 2005-04-13 2007-01-09 성균관대학교산학협력단 새로운 온도 및 ｐＨ 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8070810B2 (en) * 2006-01-12 2011-12-06 Histogenics Corporation Method for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
GB0619175D0 (en) * 2006-09-29 2006-11-08 Univ Nottingham Polymer
CN101541857B (zh) * 2006-11-27 2012-12-12 阿克塔马克斯手术器材有限责任公司 多官能聚环氧烷、水凝胶和组织粘合剂
JP2010519183A (ja) * 2007-02-06 2010-06-03 インセプト エルエルシー 生理溶液の溶出のためのタンパク質の沈殿を用いる重合
US20080220047A1 (en) * 2007-03-05 2008-09-11 Sawhney Amarpreet S Low-swelling biocompatible hydrogels
EP2537539B1 (en) 2007-04-13 2019-04-03 Kuros Biosurgery AG Polymeric Tissue Sealant
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
ES2604968T3 (es) * 2008-04-28 2017-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
NZ599583A (en) * 2009-10-29 2013-09-27 Ascendis Pharma As Sterilization of biodegradable hydrogels
EP2438930A1 (en) * 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate

Also Published As

Publication number Publication date
BR112012002280A2 (pt) 2016-06-14
ZA201200686B (en) 2012-10-31
BR112012002280B1 (pt) 2020-04-07
JP2013500950A (ja) 2013-01-10
CN102573913B (zh) 2014-06-18
CA2769162C (en) 2017-12-05
JP5904941B2 (ja) 2016-04-20
AU2010277556B2 (en) 2014-10-09
LT2459220T (lt) 2020-12-28
RU2554854C2 (ru) 2015-06-27
EP2459220B1 (en) 2020-09-09
EP3782649A1 (en) 2021-02-24
HUE052816T2 (hu) 2021-05-28
MY156872A (en) 2016-04-15
ES2833035T3 (es) 2021-06-14
KR20120090039A (ko) 2012-08-16
EP2459220A1 (en) 2012-06-06
RU2554854C9 (ru) 2017-02-03
IL217743A0 (en) 2012-03-29
EP3782649B1 (en) 2025-05-14
HK1173082A1 (en) 2013-05-10
AU2010277556A1 (en) 2012-02-02
SI2459220T1 (sl) 2020-12-31
SG177761A1 (en) 2012-03-29
MX343925B (es) 2016-11-29
CA2769162A1 (en) 2011-02-03
RU2012107137A (ru) 2013-09-10
US20120156259A1 (en) 2012-06-21
US11559482B2 (en) 2023-01-24
PL2459220T3 (pl) 2021-03-08
WO2011012715A1 (en) 2011-02-03
IL217743A (en) 2017-01-31
KR101770844B1 (ko) 2017-08-23
CN102573913A (zh) 2012-07-11
NZ597960A (en) 2013-07-26
HRP20201609T1 (hr) 2021-01-08

Similar Documents

Publication Publication Date Title
MX2012001061A (es) Hidrogeles biodegradables insolubles en agua a base de polietilenglicol.
CY1124718T1 (el) Ανθεκτικο στη διασπαση υαλουρονικο χαμηλου μοριακου βαρους με σταυροδεσμους
CY1121106T1 (el) Συζευγματα λιπαρων οξεων της κουετιαπινης, διαδικασια παρασκευης και χρησης της
MX2021003184A (es) Hidrogeles de acido hialuronico degradables.
IN2014MN02248A (es)
MEP88208A (en) Leptomycin derivatives
PH12020550032A1 (en) Gel comprising chlorhexidine
GT201000144A (es) " composiciones farmaceuticas "
UY31350A1 (es) (carboxilalquilenfenil)feniloxamidas, procedimiento para su preparación y su utilización como medicamentos
MX2012004499A (es) Esterilizacion de hidrogeles biodegradables.
AR061514A1 (es) Formulaciones pobres en espuma para la proteccion de las plantas
BR112012028308A2 (pt) formulações oftálmicas de galactomanano estabilizadas
MY158476A (en) Pharmaceutical composition for emergency contraception
NZ608239A (en) Aqueous drug delivery system comprising off - flavor masking agent
CO6640262A2 (es) Composiciones farmacéuticas y métodos para su elaboración
PE20110407A1 (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
PH12013500223A1 (en) Oral care product and methods of use and manufacture thereof
CL2012000744A1 (es) Proceso para preparar un conjugado de polisacáridos capsulares tipo 5 o tipo 8 de s. aureus y una molécula transportadora; conjugado de polisacáridos; y composición inmunogénica que lo comprende.
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.
CO2021010366A2 (es) Composiciones de administración farmacéutica y usos de las mismas
MX2013006197A (es) Una composicion de enjuage bucal de microemulsion antimicrobiana.
AR100425A1 (es) Composición en forma de partículas compactadas
AR099328A1 (es) Conjugados de factor vii
ES2568457T3 (es) Uso de polímeros con grupos carboxilo en combinación con cationes divalentes para la formación de una capa protectora
GEP20125618B (en) Biodegradable copolymers of poly (ester urea) and method for obtaining same

Legal Events

Date Code Title Description
FG Grant or registration